Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections

References

• Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-64
   PubMed Web of Science ®Google Scholar
• Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial therapy for intra-abdominal infections. Drugs 2012;72:e17-32
   PubMed Web of Science ®Google Scholar
• Eckmann C, Dryden M, Montravers P, et al. Antimicrobial treatment of “complicated” intra-abdominal infections and the new IDSA guidelines? A commentary and an alternative European approach according to clinical definitions. Eur J Med Res 2011;16:115-26
   PubMed Web of Science ®Google Scholar
• Vincent JL, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009;302:2323-9
   PubMed Web of Science ®Google Scholar
• Krepel CJ, Gohr CM, Edmiston CE, Condon RE. Surgical sepsis: constancy of antibiotic susceptibility of causative organisms. Surgery 1995;117:505-9
   PubMedGoogle Scholar
• Röhrborn A, Wacha H, Schöffel U, et al. Coverage of enterococci in community acquired secondary peritonitis: results of a randomized trial. Surg Infect (Larchmt) 2000;1:95-107
   PubMedGoogle Scholar
• Gauzit R, Péan Y, Barth X, Top Study Team. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a French prospective observational multicenter study. Surg Infect (Larchmt) 2009;10:119-27
   PubMed Web of Science ®Google Scholar
• Cercenado E, Torroba L, Cantón R, et al. Multicenter study evaluating the role of enterococci in secondary bacterial peritonitis. J Clin Microbiol 2010;48:456-9
   PubMed Web of Science ®Google Scholar
• Sitges-Serra A, López MJ, Girvent M, et al. Postoperative enterococcal infection after treatment of complicated intra-abdominal sepsis. Br J Surg 2002;89:361-7
   PubMed Web of Science ®Google Scholar
• Guirao X. What should and should not be covered in intraabdominal infection. Article in Spanish Enferm Infecc Microbiol Clin 2010;28(Suppl 2):32-41
   PubMed Web of Science ®Google Scholar
• Harbarth S, Uckay I. Are there patients with peritonitis who require empiric therapy for enterococcus? Eur J Clin Microbiol Infect Dis 2004;23:73-7
   PubMed Web of Science ®Google Scholar
• Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-20
   PubMed Web of Science ®Google Scholar
• Maseda E, Mensa J, Valía JC, et al. Bugs, hosts and ICU environment: countering pan-resistance in nosocomial microbiota and treating bacterial infections in the critical care setting. Rev Esp Quimioter 2013;26:312-31
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Multidrug-resistant Bacteroides fragilis – Seattle, Washington, 2013. MMWR Morb Mortal Wkly Rep 2013;62:694-6
   PubMedGoogle Scholar
• Nagy E, Urban E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria. Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 2011;17:371-9
   PubMed Web of Science ®Google Scholar
• Frakking FN, Rottier WC, Dorigo-Zetsma JW, et al. Appropriateness of empirical treatment and outcome in bacteremia caused by extended-spectrum-β-lactamase-producing bacteria. Antimicrob Agents Chemother 2013;57:3092-9
   PubMed Web of Science ®Google Scholar
• Babinchak T, Badal R, Hoban D, et al. Trends in susceptibility of selected Gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn Microbiol Infect Dis 2013;76:379-81
   PubMed Web of Science ®Google Scholar
• Sheng WH, Badal RE, Hsueh PR; SMART Program. Distribution of extended-spectrum β-lactamases, AmpC β-lactamases, and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal infections in the Asia-Pacific region: results of the study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2013;57:2981-8
   PubMed Web of Science ®Google Scholar
• Cantón R, Loza E, Aznar J, et al. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010). Rev Esp Quimioter 2011;24:223-32
   PubMed Web of Science ®Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18:657-86
   PubMed Web of Science ®Google Scholar
• Rubio-Perez I, Martin-Perez E, Garcia DD, et al. Extended-spectrum beta-lactamase-producing bacteria in a tertiary care hospital in Madrid: epidemiology, risk factors and antimicrobial susceptibility patterns. Emerg Health Threats J 2012;5
   PubMedGoogle Scholar
• Dunne WM Jr, Hardin DJ. Use of several inducer and substrate antibiotic combinations in a disk approximation assay format to screen for AmpC induction in patient isolates of Pseudomonas aeruginosa, Enterobacter spp., Citrobacter spp., and Serratia spp. J Clin Microbiol 2005;43:5945-9
   PubMedGoogle Scholar
• Livermore DM, Brown DF. Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother 2001;48(Suppl 1):59-64
   PubMedGoogle Scholar
• Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008;62(Suppl 1):i1-9
   Web of Science ®Google Scholar
• Miró E, Agüero J, Larrosa MN, et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 2013;32:253-9
   PubMed Web of Science ®Google Scholar
• Denisuik AJ, Lagacé-Wiens PR, Pitout JD, et al. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11. J Antimicrob Chemother 2013;68(Suppl 1):i57-65
   PubMedGoogle Scholar
• Cejas D, Fernández Canigia L, Quinteros M, et al. Plasmid-Encoded AmpC (pAmpC) in Enterobacteriaceae: epidemiology of microorganisms and resistance markers. Rev Argent Microbiol 2012;44:182-6
   PubMedGoogle Scholar
• Hombach M, Mouttet B, Bloemberg GV. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates. J Antimicrob Chemother 2013;68:2092-8
   PubMed Web of Science ®Google Scholar
• Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-90
   PubMed Web of Science ®Google Scholar
• Palzkill T. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 2013;1277:91-104
   PubMed Web of Science ®Google Scholar
• Jones RN, Flonta M, Gurler N, et al. Resistance surveillance program report for selected European nations (2011). Diagn Microbiol Infect Dis 2014;78:429-36
   PubMed Web of Science ®Google Scholar
• Tellado JM, Sen SS, Caloto MT, et al. Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain. Scand J Infect Dis 2007;39:947-55
   PubMed Web of Science ®Google Scholar
• Augustin P, Dinh AT, Valin N, et al. Pseudomonas aeruginosa post-operative peritonitis: clinical features, risk factors, and prognosis. Surg Infect (Larchmt) 2013;14:297-303
   PubMed Web of Science ®Google Scholar
• Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006;34:1589-96
   PubMed Web of Science ®Google Scholar
• Georges B, Conil JM, Dubouix A, et al. Risk of emergence of Pseudomonas aeruginosa resistance to beta-lactam antibiotics in intensive care units. Crit Care Med 2006;34:1636-41
   PubMed Web of Science ®Google Scholar
• Bonomo RA, Szabo D. Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 2006;43(Suppl 2):S49-56
   PubMed Web of Science ®Google Scholar
• Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-36
   PubMed Web of Science ®Google Scholar
• Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008;13:19045
   PubMedGoogle Scholar
• Riera E, Cabot G, Mulet X, et al. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem. J Antimicrob Chemother 2011;66:2022-7
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Schell S, et al. Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections. Surg Infect (Larchmt) 2008;9:335-47
   PubMed Web of Science ®Google Scholar
• Shlaes DM. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci 2013;1277:105-14
   PubMed Web of Science ®Google Scholar
• Hong MC, Hsu DI, Bounthavong M. Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination. Infect Drug Resist 2013;6:215-23
   PubMedGoogle Scholar
• Livermore DM, Mushtaq S, Ge Y. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2010;65:1972-4
   PubMed Web of Science ®Google Scholar
• Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 2010;23:160-201
   PubMed Web of Science ®Google Scholar
• Sader HS, Rhomberg PR, Farrell DJ, Jones RN. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob Agents Chemother 2011;55:2390-4
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Chung P, Adam H, et al. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant Gram-negative bacilli. Drugs 2014;74:31-51
   PubMed Web of Science ®Google Scholar
• Moyá B, Zamorano L, Juan C, et al. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54:3933-7
   PubMed Web of Science ®Google Scholar
• Moyá B, Dötsch A, Juan C, et al. Beta-lactam resistance response triggered by inactivation of a nonessential penicillin-binding protein. PLoS Pathog 2009;5:e1000353
   Google Scholar
• Melhem M, Forrest A, Rubino C, et al. Pharmacokinetic-pharmacodynamic (PK-PD) target attainment (TA) analyses supporting the selection of in vitro susceptibility test interpretive criteria for ceftolozane/tazobactam (TOL/TAZ) against Pseudomonas aeruginosa. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. P1743
   Google Scholar
• Hershberger E, Mouksassi M, Steenbergen J, et al. Pharmacokinetic (PK)/Pharmacodynamic (PD) target attainment (TA) using different dosing strategies for CXA-201 (CXA 101 in combination with tazobactum (TAZ) against difficult to treat Gram-negative Pathogens. Abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases; Milan, Italy; 2011. P1520
   Google Scholar
• Snydman DR, McDermott LA, Jacobus NV. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob Agents Chemother 2014;58:1218-23
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Castanheira M, Jones RN. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP442
   Google Scholar
• Farrell DJ, Flamm RK, Sader HS, Jones RN. Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012). Antimicrob Agents Chemother 2013;57:6305-10
   PubMed Web of Science ®Google Scholar
• Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Int J Antimicrob Agents 2014;43:533-9
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Castanheira M, et al. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). J Antimicrob Chemother 2014. [Epub ahead of print]
   Google Scholar
• Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012;18:268-81
   PubMed Web of Science ®Google Scholar
• Sader HS, Farrell DJ, Flamm RK, Jones RN. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). J Infect 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing intraabdmonial infections in European hospitals (2011-2012): a report from an International antimicrobial surveillance program. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP446
   Google Scholar
• McCurdy S, Petersen PJ, Steenbergen J, et al. Ceftolozane/tazobactam activity against Gram-negative bacteria causing urinary tract infections in European hospitals (2011-2012): a report from an International antimicrobial surveillance program. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP445
   Google Scholar
• Farrell DJ, Sader HS, Flamm RK, Jones RN. Ceftolozane/tazobactam activity when tested against Gram-negative bacteria isolates from hospitalized patients with pneumonia in European hospitals (2011-2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP443
   Google Scholar
• Titelman E, Karlsson IM, Ge Y, Giske CG. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn Microbiol Infect Dis 2011;70:137-41
   PubMed Web of Science ®Google Scholar
• García-Castillo M, Tato M, Bou G, et al. Comparative in vitro activity of ceftolozane/tazobactam against clinical isolates of Enterobacteriaceae: results of the CENIT multi-centre study. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP447
   Google Scholar
• Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014;58:3091-9
   PubMed Web of Science ®Google Scholar
• Moyá B, Beceiro A, Cabot G, et al. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities. Antimicrob Agents Chemother 2012;56:4771-8
   PubMed Web of Science ®Google Scholar
• Riera E, Macià MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010;65:1399-404
   PubMed Web of Science ®Google Scholar
• Takeda S, Nakai T, Wakai Y, et al. In vitro and in vivo activities of a new cephalosporin, FR264205, against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007;51:826-30
   PubMed Web of Science ®Google Scholar
• Walkty A, Karlowsky JA, Adam H, et al. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob Agents Chemother 2013;57:5707-9
   PubMed Web of Science ®Google Scholar
• Tato M, García-Castillo M, Moreno-Bofarull A, et al. Comparative in vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa: results of the CENIT multi-centre study. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP448
   Google Scholar
• Farrell DJ, Sader HS, Castanheira M, Jones RN. Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 15 European countries and Israel (2011-2012). Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP444
   Google Scholar
• Bulik CC, Christensen H, Nicolau DP. In vitro potency of CXA-101, a novel cephalosporin, against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob Agents Chemother 2010;54:557-9
   PubMed Web of Science ®Google Scholar
• Zamorano L, Juan C, Fernández-Olmos A, et al. Activity of the new cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa isolates from chronically-infected cystic fibrosis patients. Clin Microbiol Infect 2010;16:1482-7
   PubMed Web of Science ®Google Scholar
• Moyá B, Zamorano L, Juan C, et al. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob Agents Chemother 2010;54:1213-17
   PubMed Web of Science ®Google Scholar
• Juan C, Zamorano L, Pérez JL, Spanish Group for the Study of Pseudomonas; Spanish Network for Research in Infectious Diseases. Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains. Antimicrob Agents Chemother 2010;54:846-51
   PubMed Web of Science ®Google Scholar
• Livermore DM, Mushtaq S, Ge Y, Warner M. Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates. Int J Antimicrob Agents 2009;34:402-6
   PubMed Web of Science ®Google Scholar
• Riera E, Macià MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010;65:1399-404
   PubMed Web of Science ®Google Scholar
• Soon RL, Forrest A, Holden PN, et al. In vitro pharmacodynamics of CXA-2001 (ceftolozane/tazobactam) against β-lactamase producing Escherichia coli. Abstracts of the 52nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; 2012. E-201
   Google Scholar
• Brown NP, Pillar CM, Draghi DC, et al. Mode of action of CXA-101 based on minimum bactericidal concentration analysis and time-kill kinetic analysis. Abstracts of the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy & the Infectious Disease Society of America 46th Annual Meeting; Washington DC, USA; 2008. F1-358
   Google Scholar
• Sader HS, Rhomberg PR, Jones RN. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains. Antimicrob Agents Chemother 2014;58:2434-7
   PubMedGoogle Scholar
• Craig WA, Andes DR. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 2013;57:1577-82
   PubMed Web of Science ®Google Scholar
• Andes D, Alex L. In vivo pharmacodynamics of ceftolozane against Streptococcus pneumoniae and Pseudomonas aeruginosa across a wide range of MICs in a neutropenic murine thigh infection model. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. P1735
   Google Scholar
• Jacqueline C, Roquilly A, Desessard C, et al. Efficacy of ceftolozane in a murine model of Pseudomonas aeruginosa acute pneumonia: in vivo antimicrobial activity and impact on host inflammatory response. J Antimicrob Chemother 2013;68:177-83
   PubMed Web of Science ®Google Scholar
• Jacqueline C, Desessard C, Roquilly A, et al. 50% Effective dose (ED50) determination of CXA-101 (CXA) alone or in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (EC) strains: Comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP). Abstracts of the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; San Francisco, CA, USA; 2009. F1-2000
   Google Scholar
• Jacqueline C, Desessard C, Amador G, et al. ED50 determination of CXA-101 alone and in combination with tazobactam (TAZ) for treating experimental peritonitis in mice due to ESBL-producing Klebsiella pneumoniae (KP) strains: Comparison with ceftazidime (CAZ) and piperacillin/tazobactam (TZP). Abstracts of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Boston, MA, USA; 2010. B-708
   Google Scholar
• Bulik CC, Tessier PR, Keel RA, et al. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse Gram-negative organisms. Antimicrob Agents Chemother 2012;56:544-9
   PubMed Web of Science ®Google Scholar
• Vanscoy B, Mendes RE, Castanheira M, et al. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother 2013;57:4134-8
   PubMed Web of Science ®Google Scholar
• Ge Y, Whitehouse MJ, Friedland I, Talbot GH. Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions. Antimicrob Agents Chemother 2010;54:3427-31
   PubMed Web of Science ®Google Scholar
• Miller B, Hershberger E, Benziger D, et al. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob Agents Chemother 2012;56:3086-91
   PubMed Web of Science ®Google Scholar
• Chandorkar G, Huntington JA, Gotfried MH, et al. Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. J Antimicrob Chemother 2012;67:2463-9
   PubMed Web of Science ®Google Scholar
• Wooley M, Miller B, Krishna G, et al. Impact of renal function on the pharmacokinetics and safety of ceftolozane-tazobactam. Antimicrob Agents Chemother 2014;58:2249-55
   PubMed Web of Science ®Google Scholar
• Wooley M, Bernardo P, Miller B, et al. Evaluation of the potential for drug–drug interactions between ceftolozane/tazobactam and drugs metabolised by CYP1A2 or CYP3A4 or transported by OAT1 and OAT3. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP450
   Google Scholar
• Wise R, Logan M, Cooper M, Andrews JM. Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin. Antimicrob Agents Chemother 1991;35:1081-4
   PubMed Web of Science ®Google Scholar
• Wagenlehner F, Umeh O, Huntington J, et al. Efficacy and safety of ceftolozane/tazobactam versus levofloxacin in the treatment of complicated urinary tract infections (cUTI)/pyelonephritis in hospitalised adults: results from the phase 3 aspect-cUTI trial. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP449
   Google Scholar
• Lucasti C, Hershberger E, Miller B, et al. A Multicenter, double-blind, randomized, Phase 2 study to assess the safety and efficacy of ceftolozane/tazobactam (TOL/TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI). Abstracts of the 53rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy; Denver, CO, USA; 2013. K1709
   Google Scholar
• Eckmann C, Hershberger E, Miller B, et al. Efficacy and safety of ceftolozane/tazobactam versus meropenem in the treatment of complicated intra-abdominal infections (cIAI) in hospitalised adults: results from the phase 3 aspect-cIAI trial. Abstracts of the 24th European Congress of Clinical Microbiology and Infectious Diseases; Barcelona, Spain; 2014. eP0266a
   Google Scholar
• Gram-negative: ceftolozane/tazobactam. Available from: www.cubist.com/products/ceftolozane-tazobactam
   Google Scholar